Please ensure Javascript is enabled for purposes of website accessibility

Why Amicus Therapeutics Stock Is Rising Today

By George Budwell - Feb 4, 2020 at 12:51PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An analyst upgrade is driving Amicus' stock higher today.

What happened

Shares of rare-disease specialist Amicus Therapeutics (FOLD 1.70%) are marching higher today. Specifically, the drugmaker's stock is up by 10% as of 12:45 p.m. EST. 

What's driving this double-digit rally today? The biotech's shares are jumping in response to a noteworthy upgrade from Cantor Fitzgerald's analyst Eliana Merle. The big-ticket item is that Merle's forward-looking price target of $20 per share implies a whopping 124% upside potential -- that is, relative to where the biotech's stock closed on Monday.  

Stacks of wooden blocks with upward-facing arrows on them grow taller as they move to the right.

Image source: Getty Images.

So what

Prior to today's hefty rally, Amicus' stock was clearly stuck in a rut. Weighed down by concerns over a rival Pompe disease treatment from French drug giant Sanofi and an already-rich valuation, Amicus' stock had been slowly losing ground since the end of the first quarter of 2019. In short, investors were growing increasingly concerned that Amicus' sky-high valuation may not be justified. Cantor, for its part, apparently doesn't think the biotech's eye-popping price-to-sales ratio of 15.7 is a problem in the least. 

Now what

Is it time to buy? Amicus' experimental Pompe disease treatment known as AT-GAA could one day generate upwards of $2 billion in sales. So, if that line holds true, the biotech's stock should not only double from current levels, but it could easily triple in value within a few short years. As such, it might indeed be worthwhile to take a flier on this top orphan drug stock on the heels of this overwhelmingly positive analyst upgrade.  

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amicus Therapeutics, Inc. Stock Quote
Amicus Therapeutics, Inc.
FOLD
$10.78 (1.70%) $0.18
Sanofi Stock Quote
Sanofi
SNY
$52.67 (1.02%) $0.53

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
319%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.